UNSPSC 51286803: Nitroxoline

This classification denotes a quinolone antibiotic with the molecular formula C9H6N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A8M33244M6, chemically known as 8-quinolinol, 5-nitro- but more generally known as nitroxoline, which bears US NIH Compound Identifier 19910. European Medicines Agency schedules Nitroxoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09331MIG. The term NITROXOLINE is an International Non-Proprietary Name.

The World Health Organization schedules nitroxoline in its Anatomical Therapeutic Chemical (ATC) Classification. NITROXOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC1C2NCCCC2C([N](=O)O)CC1.

UNSPSC 51286803 Nitroxoline is a Commodity code. State and local governments procure nitroxoline—an antibiotic used in urinary tract and other bacterial infections—as a pharmaceutical input through cooperative purchasing arrangements and direct procurement. The recent opportunities block shows limited nitroxoline-specific demand; the two posted records tag opportunities under this code but neither actually solicits nitroxoline. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets—both fluoroquinolone and tetracycline antibiotics, not nitroxoline. That award was completed under an Invitation for Bid process with a 12-month initial term and two renewal options. Seminole County, Florida posted an IFB on June 30, 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, also unrelated to nitroxoline. The mismatch suggests the code receives minimal state and local solicitation activity aligned to nitroxoline's actual pharmaceutical scope.

Geographic activity centers on Illinois and Florida based on recent records, though the volume is insufficient to characterize concentration. The Illinois Department of Public Health operates through cooperative purchasing vehicles such as MMCAP Infuse to aggregate pharmaceutical spend across renewal cycles. Seminole County's procurement, while posted in June 2026, carried a response deadline of July 26, 2023, indicating a stale or misfiled record. State and local procurement under nitroxoline appears to flow through either cooperative pharmaceutical agreements (as in Illinois) or direct county health department procurement, though the recent opportunities block shows no active open solicitations specifically for nitroxoline. The code warrants watching for cooperative-purchasing framework agreements that might bundle nitroxoline with broader antibiotic portfolios, but current activity does not support immediate pursuit.